FDA Guidance Raises Prospect Of More INDs For Supplement Research
This article was originally published in The Tan Sheet
Executive Summary
An FDA draft guidance that seeks to clarify when an investigational new drug application should be filed may add logistical knots to the process of studying foods and dietary ingredients, stakeholders say.
You may also be interested in...
Resveratrol Partners Asks For IND Waiver On Macular Degeneration Claim
Resveratrol Partners submitted a petition that argues FDA regulations slow the development of health care products to address public health needs, such as the treatment of wet age-related macular degeneration. “It’s the public’s welfare, it’s not about rules and regulations,” says the firm’s managing partner, Bill Sardi.
Resveratrol Partners Asks For IND Waiver On Macular Degeneration Claim
Resveratrol Partners submitted a petition that argues FDA regulations slow the development of health care products to address public health needs, such as the treatment of wet age-related macular degeneration. “It’s the public’s welfare, it’s not about rules and regulations,” says the firm’s managing partner, Bill Sardi.
OTC Probiotics Face Challenging Regulatory Framework
The development of OTC drugs based on probiotics requires a regulatory system more receptive to research on the microorganisms' use as therapeutic ingredients, according to microbiologist Gary Huffnagle.